ReviewCurrent medical imaging2026
Disseminated Tuberculosis Masquerading as Malignancy in an Immunocompetent Middle-aged Woman: A Multiorgan Imaging Case Report and Updated Review for Clinicians
Review in Current medical imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDisseminated tuberculosis (dTB) can occur in immunocompetent adults, frequently mimicking metastatic malignancy, thereby delaying the diagnosis. CASE PRESENTATION: A young woman without known immunosuppression developed multisystem disease involving the peritoneum/ovaries, hepatobiliary structures, lymph nodes, adrenals, and thoracolumbar spine. CT/MRI and PET/CT suggested widespread neoplastic disease. Because FDG avidity is nonspecific, we prioritized histologic confirmation. Surgical exploration and targeted biopsies showed necrotizing granulomatous inflammation compatible with tuberculosis; microbiologic testing supported the diagnosis. The patient commenced directly observed first-line therapy (isoniazid, rifampin, pyrazinamide, ethambutol) as the intensive phase, followed by an isoniazid-rifampin continuation phase. Under treatment, symptoms improved, and interval imaging showed regression of inflammatory lesions.
conclusionIn cancer-like, multisystem presentations, even in apparently immunocompetent hosts, tissue diagnosis is decisive, and imaging should primarily guide sampling. Early recognition and standardized therapy can prevent irreversible morbidity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.